PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Bioscience Research & Development, Grifols, Barcelona, Spain.\', \'IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona (UAB), Bellaterra, Barcelona, Spain.\', \'Laboratorio Coronavirus. Departamento de Biología Molecular y Celular, CNB-CSIC, Madrid, Spain.\', \'UAB, CReSA (IRTA-UAB), Campus de la Universitat Autònoma de Barcelona (UAB), Bellaterra, Barcelona, Spain.\', \'Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, Universitat Autònoma de Barcelona (UAB), Bellaterra, Barcelona, Spain.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.2217/imt-2020-0220
?:hasPublicationType
?:journal
  • Immunotherapy
is ?:pmid of
?:pmid
?:pmid
  • 32900263
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.986
?:rankingScore_hIndex
  • 33
?:title
  • Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32900263>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32900263>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all